Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7949211rdf:typepubmed:Citationlld:pubmed
pubmed-article:7949211lifeskim:mentionsumls-concept:C0278488lld:lifeskim
pubmed-article:7949211lifeskim:mentionsumls-concept:C0332174lld:lifeskim
pubmed-article:7949211lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:7949211lifeskim:mentionsumls-concept:C0023413lld:lifeskim
pubmed-article:7949211lifeskim:mentionsumls-concept:C0026259lld:lifeskim
pubmed-article:7949211lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:7949211pubmed:issue2lld:pubmed
pubmed-article:7949211pubmed:dateCreated1994-12-22lld:pubmed
pubmed-article:7949211pubmed:abstractTextA phase II study to test the toxicity and the efficacy of a weekly combination of Mitoxantrone, 5-Fluorouracil and L-Leucovorin (MFL) was carried out in 43 patients with metastatic breast cancer. Chemotherapy consisted of mitoxantrone 4 mg/m2, 5-fluorouracil 375 mg/m2, and L-leucovorin 100 mg/m2 on day 1, weekly. Patient characteristics were: median age 53 years (range 36-65); estrogen receptor (ER) status was known in 26 patients and of these 15 (57.7%) patients were ER-positive and 11 (42.3%) ER-negative. Of the 43 patients, 25 (58.1%) and 18 (41.9%) patients had received prior adjuvant chemotherapy and prior adjuvant endocrine treatment, respectively. MFL was administered to 22 (51.1%) patients as first line chemotherapy for advanced disease, while 21 (48.9%) patients had received 1 to 2 cytotoxic regimens for metastatic disease. The dominant sites of metastases were: soft tissue in 11 (25.5%) patients, bone in 8 (18.6%) patients and viscera in 24 (55.9%). All patients were assessable for toxicity: only 8 patients experienced WHO grade 3 leukopenia. Thrombocytopenia, diarrhea, stomatitis, and nausea/vomiting were negligible. Anemia and alopecia were not observed. Thirty-nine patients were assessable for response: overall response rate was 28.2% (complete response 7.7% and partial response 20.5%). Median duration of response was 12 months (range 6-34). Patients with no prior anthracyclines had a 42.1% response rate compared to 15% in patients who had received anthracyclines. Median overall survival of the 43 patients was 6 months (range 1-34). Weekly MFL is a well-tolerated and a moderately effective regimen for the treatment of metastatic breast cancer.lld:pubmed
pubmed-article:7949211pubmed:languageenglld:pubmed
pubmed-article:7949211pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7949211pubmed:citationSubsetIMlld:pubmed
pubmed-article:7949211pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7949211pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7949211pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7949211pubmed:statusMEDLINElld:pubmed
pubmed-article:7949211pubmed:issn0167-6806lld:pubmed
pubmed-article:7949211pubmed:authorpubmed-author:NashDDlld:pubmed
pubmed-article:7949211pubmed:authorpubmed-author:MerliniLLlld:pubmed
pubmed-article:7949211pubmed:authorpubmed-author:RepettoLLlld:pubmed
pubmed-article:7949211pubmed:authorpubmed-author:CamporaEElld:pubmed
pubmed-article:7949211pubmed:authorpubmed-author:GiudiciSSlld:pubmed
pubmed-article:7949211pubmed:authorpubmed-author:VenturinoAAlld:pubmed
pubmed-article:7949211pubmed:authorpubmed-author:MigliettaLLlld:pubmed
pubmed-article:7949211pubmed:authorpubmed-author:GardinGGlld:pubmed
pubmed-article:7949211pubmed:authorpubmed-author:TestoreFFlld:pubmed
pubmed-article:7949211pubmed:authorpubmed-author:LanfrancoCClld:pubmed
pubmed-article:7949211pubmed:issnTypePrintlld:pubmed
pubmed-article:7949211pubmed:volume30lld:pubmed
pubmed-article:7949211pubmed:ownerNLMlld:pubmed
pubmed-article:7949211pubmed:authorsCompleteNlld:pubmed
pubmed-article:7949211pubmed:pagination133-7lld:pubmed
pubmed-article:7949211pubmed:dateRevised2006-4-24lld:pubmed
pubmed-article:7949211pubmed:meshHeadingpubmed-meshheading:7949211-...lld:pubmed
pubmed-article:7949211pubmed:meshHeadingpubmed-meshheading:7949211-...lld:pubmed
pubmed-article:7949211pubmed:meshHeadingpubmed-meshheading:7949211-...lld:pubmed
pubmed-article:7949211pubmed:meshHeadingpubmed-meshheading:7949211-...lld:pubmed
pubmed-article:7949211pubmed:meshHeadingpubmed-meshheading:7949211-...lld:pubmed
pubmed-article:7949211pubmed:meshHeadingpubmed-meshheading:7949211-...lld:pubmed
pubmed-article:7949211pubmed:meshHeadingpubmed-meshheading:7949211-...lld:pubmed
pubmed-article:7949211pubmed:meshHeadingpubmed-meshheading:7949211-...lld:pubmed
pubmed-article:7949211pubmed:meshHeadingpubmed-meshheading:7949211-...lld:pubmed
pubmed-article:7949211pubmed:meshHeadingpubmed-meshheading:7949211-...lld:pubmed
pubmed-article:7949211pubmed:meshHeadingpubmed-meshheading:7949211-...lld:pubmed
pubmed-article:7949211pubmed:meshHeadingpubmed-meshheading:7949211-...lld:pubmed
pubmed-article:7949211pubmed:year1994lld:pubmed
pubmed-article:7949211pubmed:articleTitlePhase II study of weekly mitoxantrone, 5-fluorouracil, and leucovorin in metastatic breast cancer.lld:pubmed
pubmed-article:7949211pubmed:affiliationDepartment of Medical Oncology I, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.lld:pubmed
pubmed-article:7949211pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7949211pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:7949211pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed